InnoMedica

Executive Summary

InnoMedica is a Swiss pharmaceutical company leveraging its proprietary nanocarrier technology to develop targeted therapies with improved efficacy and reduced side effects. Founded in 2013 and headquartered in Lucerne, the company focuses on neurology and oncology, with lead programs in Parkinson's disease and various cancers. Its platform enables controlled release and site-specific delivery of active ingredients, addressing key limitations of conventional treatments. By encapsulating drugs in biocompatible nanocarriers, InnoMedica aims to enhance therapeutic outcomes and minimize systemic toxicity, potentially offering first- or best-in-class solutions.

Upcoming Catalysts (preview)

• Q2 2026Phase 1/2a clinical trial results for lead Parkinson's disease candidate40% success
• H2 2026Strategic partnership or licensing deal for oncology platform35% success
• Q3 2026Completion of Series B financing round to fund clinical development70% success